Neuland Laboratories Q2 FY27 Earnings Call: Guides Rs. 1,800 Cr Capex, Peptide Reactor Scales To 500L (NEULANDLAB)

Neuland Laboratories Ltd held its Q2 FY27 earnings call on November 03, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Below-Trend Quarter; H1 Largely on Track

• Q2 FY 2026-2027 total income declined to Rs.457.2 Cr — down from Rs.516.1 Cr in Q2 FY 2025-2026, though H1 FY 2026-2027 total income grew to Rs.1,107.2 Cr from Rs.816.7 Cr in H1 FY 2025-2026.
• EBITDA fell to Rs.104.6 Cr (22.9% margin) — versus Rs.156.9 Cr (30.4%) in Q2 FY 2025-2026; gross margin was 59.4% vs 60.1% YoY.
• PAT dropped to Rs.51.1 Cr — from Rs.96.5 Cr in Q2 FY 2025-2026; EPS for the quarter stood at Rs.39.85 per share.
• Working capital rose to 104 days of sales — up from 84 days in Q1 FY 2026-2027, though management highlighted an improvement from 155 days earlier; H1 capex outflow was Rs.261 Cr with free cash flow of Rs.99 Cr and a net cash position of Rs.208 Cr.
• Cost pressures from geopolitics — management attributed H1 FY 2026-2027 input cost increases (raw material volatility, freight and logistics escalation) to the geopolitical environment and ongoing conflicts in different parts of the world.
• Q2 came in below the trend of recent quarters — though H1 FY 2026-2027 was largely in line with management's expectations; quarterly "lumpiness" from larger individual commercial shipments amplifies timing shifts.

CMS Outgrew GDS; Concentration Persists at Scale

• FY 2025-2026 was the first year CMS revenue exceeded GDS — management believes increasing CMS contribution will remain an important part of Neuland's evolution over the coming years.
• Q2 FY 2026-2027 CMS revenue was Rs.214 Cr — recognized from only 5-6 commercial molecules, with several smaller intermediates (e.g., ophthalmic products) ordered only once in 2-3 years; recent CMS revenues have been majorly commercial rather than development.
• Lumpiness scales with the business — ~10 years ago the largest molecule was Rs.40 Cr/year within a Rs.100 Cr CMS business; today the business is roughly 10x larger with the concentration ratio unchanged. Management cited Eli Lilly as industry context, where the largest drug contributes 50-60% of revenues.
• Lumpiness would reduce only with dramatically more large contributors — e.g., from 3-4 molecules to 30 over the next 5-10 years; management cannot indicate lumpiness will go away within 18 months.
• No new CMS launch in the last 2-3 quarters — the last launch occurred ~1 year before the call; management expects more launches over the next 1-2 years (from Q2 FY 2026-2027).
• Top five customers contribute 68% of revenues (Q2 FY 2026-2027); management said peptide capex (Modules 2, 3 and 4) would continue even if the current CMS/commercial business were negatively impacted, while the Kakinada investment could "probably" be modulated or deferred.

From 50L to 500L Reactors; Monetization Still Ahead

• Peptide PPQ-related revenues are 6-9 months away from the Q2 FY 2026-2027 call, per CEO Saharsh Davuluri; peptide revenues booked to date are development-linked and "not substantial," with the MSA-to-commercial-supply pivot expected in the same window.
• Roughly 1.5-2 years to commercial revenues from the peptide facility — Davuluri endorsed as "a reasonable expectation" the timeline of MSA revenues beginning 6-9 months out and commercial revenues a further 6-9 months after that.
• Idle peptide-facility costs will be borne by Neuland — Davuluri said idle time will happen "for sure" over the next 1-1.5 years from the Q2 FY 2026-2027 call, since the facility was built for a portfolio of projects rather than a single customer-funded plant.
• Largest GMP SPPS reactor scaled from 50 liters to 500 liters as of Q2 FY 2026-2027, with management looking at 1,000 liters (period unspecified); Neuland has manufactured peptide chains of 40+ amino acids to date.
• ~Rs.250 Cr spent on Peptide Module 1 so far (as of Q2 FY 2026-2027); Module 2 configuration is not yet crystallized, with management aiming to finalize it within the next 3-6 months (by around Q1 FY 2027-2028).
• ~Rs.1,800 Cr capex guided over the next three years (FY 2026-2027 to FY 2028-2029) — described as a broad number that will be revisited, with the Kakinada site one factor in the figure.
• Management cited a Global Data database showing 1,000 synthetic peptides between IND and commercial stages — up from 500 as of Jan 2025; Neuland's stated goal is to be a dominant recognized player in manufacturing APIs for these peptide therapeutics, catering to the diverse portfolio rather than a single weight-loss drug or the next GLP-1.

134 Acres at Kakinada; New R&D Center by Early FY28

• ~134 acres acquired at Kakinada, Andhra Pradesh in Q2 FY 2026-2027 — management urged investors to view the investment from a long-term return perspective; the three existing sites (Unit 1, Unit 2, Unit 3) together span 60 acres.
• Kakinada could go to 200 acres over the next two years (through FY 2028-2029) — Davuluri confirmed the current commitment is 134 acres, responding to analyst Sajal Kapoor's flag of a first right of refusal on an additional ~60 acres.
• New process R&D center at Genome Valley, Hyderabad expected fully operational by early FY 2027-2028 — a process development facility (not med chem or route scouting) integrating process engineering, quality by design, and flow chemistry, able to generate small volumes of API in-house.
• New R&D center deepens peptides and small molecules, not new modalities — Davuluri said oligonucleotides, ADCs, and HP APIs are "not the immediate plan," with platform additions to follow later as the company remains "hyper focused" on ramping existing capabilities (timeline unspecified).
• Phase 3 projects in the pipeline increased from 8 to 13 — highlighted among Q2 FY 2026-2027 metrics; supported filings include one more NDA and 9 IND filings, with the NDA-linked product still small and biotech outcomes difficult to judge (period unspecified).
• Board approved (November 2026, FY 2026-2027) an investment to add more land around Unit 1 — expanding the Unit 1 footprint.

Specialty Muted; Staff Costs Rising; Patent Cliff Post-2030

• Specialty performance was muted in Q2 FY 2026-2027 both YoY and QoQ — AVP Finance G.V. Bhardwaj attributed this to customers facing difficulties manufacturing certain products that had previously contributed significantly; management expects resolution "probably by Q4 FY 2026-2027," based on what customers have indicated.
• Q2 FY 2026-2027 staff cost rose substantially (analyst-flagged) — Bhardwaj confirmed further headcount additions are planned in regular R&D and, on a longer note, at both the R&D center and manufacturing sites (period unspecified).
• No patent expiries before 2030 in meaningful markets — for the three large commercialized CDMO products, per G.V. Bhardwaj; Davuluri said the company is fairly certain the post-2030 dip will have no impact on its growth trajectory, as future growth will come from peptides, complex small molecules and other products.
• Peptide manufacturing execution risk — Davuluri said peptide synthesis is "quite easy to goof up" because it is considered irreversible; a misstep may require junking the entire reactor, and management needs to fortify itself with the right talent, systems, and controls.
• Potential peptide overcapacity cycle — management expects some overcapacity to emerge from GLP-1-driven euphoria, followed by a testing phase and then a correction (timeline not specified); it noted "absolutely not" overcapacity in India, while per what management has been told there may be overcapacity in China, and acknowledged overcapacity pains would impact globally including India.
• India talent constraint — management said India does not have the talent to fill a sudden surge in peptide demand; talent exists for generics but not for CDMO.

Growth Expectations Intact; No Numbers Shared

• Growth expectations remain intact for FY 2026-2027 and FY 2027-2028 — but management declined to give a specific number or even a rough range; the CEO noted "it's not that we don't know, we just don't want to share."
• Inflection framing — asked whether FY27 is an inflection year, the CEO said FY 2025-2026 was the year CMS outgrew GDS and, in that context, yes; he called the characterization subjective and left interpretation to analysts.
• Strongest RFP activity to date in FY 2026-2027 — with multiple opportunities stemming from relationships built over several years and meaningful headway with big pharma; new customers are returning quickly with second and third projects.
• AI seen as no direct threat, potentially a tailwind — Neuland, positioned IND onwards, does not expect AI to displace material generation or process design "for the foreseeable future"; Bhardwaj said AI-driven discovery-stage activity should act as a tailwind for the IND-onwards business, though Davuluri is "not quite sure" more early-stage candidates strategically benefit Neuland, whose core competence is GMP manufacturing for phase three and commercial.
• Management cannot attribute the high RFP flow to AI — no concrete evidence; it credits a combination of China plus one, favorable funding, and India being seen in a favorable light more than AI alone. Neuland is pursuing its own internal AI journey to become more efficient.
• CEO's personal caution to retail investors — the business carries opacity because Neuland does not disclose which molecules are performing well, so a poor quarter may create stress management cannot answer as transparently as an FMCG or branded company; he personally recommended Neuland only for long-term investors with appetite for that uncertainty.